4 results
To evaluate the long-term safety and tolerability of Dimebon in AD patients who have successfully completed 26 weeks of blinded treatment in the CONNECTION Study (DIM14) (hereafter referred to as *CONNECTION*).
To determine the benefit of Dimebon as compared to placebo on the primary measure of cognition and memory, the Alzheimer*s Disease Assessment Scale * cognitive subscale (ADAS-cog); andTo determine the benefit of Dimebon as compared to placebo on the…
To determine the safety and efficacy of Dimebon in patients with mild to moderate Huntington Disease
Primary objective:- To determine the safety and optimal dose of three doses of a novel therapeutic vaccine (ISA104) consisting of 12 synthetic long peptides, as well as an adjuvant agent (AmplivantTM), in patients with chronic hepatitis B (cHBV),…